Suppr超能文献

肠道微生物群失调与心血管健康:机制与治疗潜力的综合综述

Gut Dysbiosis and Cardiovascular Health: A Comprehensive Review of Mechanisms and Therapeutic Potential.

作者信息

Trehan Shubam, Singh Gurjot, Bector Gaurav, Jain Prateek, Mehta Tejal, Goswami Kanishka, Chawla Avantika, Jain Aayush, Puri Piyush, Garg Nadish

机构信息

Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, IND.

Internal Medicine, Maharaj Sawan Singh Charitable Hospital, Beas, IND.

出版信息

Cureus. 2024 Aug 16;16(8):e67010. doi: 10.7759/cureus.67010. eCollection 2024 Aug.

Abstract

Cardiovascular diseases (CVDs) are a leading cause of mortality worldwide. Recent research has identified gut dysbiosis - an imbalance in the gut microbiota - as a significant factor in the development of CVDs. This complex relationship between gut microbiota and cardiovascular health involves various mechanisms, including the production of metabolites such as trimethylamine N-oxide (TMAO) and short-chain fatty acids (SCFAs). These metabolites influence lipid metabolism, inflammation, and blood pressure regulation. In addition, the gut-brain axis and neurohormonal pathways play crucial roles in cardiovascular function. Epidemiological studies have linked gut dysbiosis to various cardiovascular conditions, highlighting the potential for therapeutic interventions. Dietary changes, probiotics, and prebiotics have shown promise in modulating gut microbiota and reducing cardiovascular risk factors. This underscores the critical role of gut health in preventing and treating CVDs. However, further research is needed to develop targeted therapies that can enhance cardiovascular outcomes.

摘要

心血管疾病(CVDs)是全球主要的死亡原因。最近的研究已确定肠道菌群失调——肠道微生物群失衡——是心血管疾病发展的一个重要因素。肠道微生物群与心血管健康之间的这种复杂关系涉及多种机制,包括三甲胺N-氧化物(TMAO)和短链脂肪酸(SCFAs)等代谢物的产生。这些代谢物会影响脂质代谢、炎症和血压调节。此外,肠脑轴和神经激素途径在心血管功能中起关键作用。流行病学研究已将肠道菌群失调与各种心血管疾病联系起来,凸显了治疗干预的潜力。饮食改变、益生菌和益生元已显示出调节肠道微生物群和降低心血管危险因素的前景。这强调了肠道健康在预防和治疗心血管疾病中的关键作用。然而,需要进一步研究以开发能够改善心血管结局的靶向治疗方法。

相似文献

1
Gut Dysbiosis and Cardiovascular Health: A Comprehensive Review of Mechanisms and Therapeutic Potential.
Cureus. 2024 Aug 16;16(8):e67010. doi: 10.7759/cureus.67010. eCollection 2024 Aug.
3
Gut macrobiotic and its metabolic pathways modulate cardiovascular disease.
Front Microbiol. 2023 Sep 26;14:1272479. doi: 10.3389/fmicb.2023.1272479. eCollection 2023.
4
Gut Dysbiosis and Immune System in Atherosclerotic Cardiovascular Disease (ACVD).
Microorganisms. 2022 Jan 5;10(1):108. doi: 10.3390/microorganisms10010108.
6
Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: A comprehensive review.
Pathol Res Pract. 2023 Sep;249:154740. doi: 10.1016/j.prp.2023.154740. Epub 2023 Aug 6.
7
Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes.
Front Endocrinol (Lausanne). 2021 Apr 7;12:632335. doi: 10.3389/fendo.2021.632335. eCollection 2021.
8
Intestinal Flora Derived Metabolites Affect the Occurrence and Development of Cardiovascular Disease.
J Multidiscip Healthc. 2022 Nov 9;15:2591-2603. doi: 10.2147/JMDH.S367591. eCollection 2022.
9
Gut microbiota and cardiovascular diseases axis.
Minerva Med. 2022 Feb;113(1):189-199. doi: 10.23736/S0026-4806.21.07527-3. Epub 2021 May 10.
10

引用本文的文献

1
A Systemic Perspective of the Link Between Microbiota and Cardiac Health: A Literature Review.
Life (Basel). 2025 Aug 7;15(8):1251. doi: 10.3390/life15081251.
4
Beyond Cholesterol: Emerging Risk Factors in Atherosclerosis.
J Clin Med. 2025 Mar 29;14(7):2352. doi: 10.3390/jcm14072352.

本文引用的文献

1
Human gut microbiota in health and disease: Unveiling the relationship.
Front Microbiol. 2022 Sep 26;13:999001. doi: 10.3389/fmicb.2022.999001. eCollection 2022.
3
Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients.
Front Cell Dev Biol. 2022 Mar 23;10:861829. doi: 10.3389/fcell.2022.861829. eCollection 2022.
4
Gut Microbiota and Cardiovascular Disease: Symbiosis Versus Dysbiosis.
Curr Med Chem. 2022;29(23):4050-4077. doi: 10.2174/0929867328666211213112949.
5
Gut-microbiota derived TMAO: A risk factor, a mediator or a bystander in the pathogenesis of atrial fibrillation?
Int J Cardiol Heart Vasc. 2021 Jun 15;34:100818. doi: 10.1016/j.ijcha.2021.100818. eCollection 2021 Jun.
6
Butyrate-producing human gut symbiont, , and its role in health and disease.
Gut Microbes. 2021 Jan-Dec;13(1):1-28. doi: 10.1080/19490976.2021.1907272.
7
Implication of Gut Microbiota in Cardiovascular Diseases.
Oxid Med Cell Longev. 2020 Sep 26;2020:5394096. doi: 10.1155/2020/5394096. eCollection 2020.
8
Gut Microbiota in Hypertension and Atherosclerosis: A Review.
Nutrients. 2020 Sep 29;12(10):2982. doi: 10.3390/nu12102982.
9
Gut Microbiota and Cardiovascular Disease.
Circ Res. 2020 Jul 31;127(4):553-570. doi: 10.1161/CIRCRESAHA.120.316242. Epub 2020 Jul 30.
10
Role of gut microbiota in cardiovascular diseases.
World J Cardiol. 2020 Apr 26;12(4):110-122. doi: 10.4330/wjc.v12.i4.110.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验